Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
Classifica tra le azioni #17312
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Prezzo delle azioni
$1.21
Capitalizzazione di mercato
$248.41M
Variazione (1 giorno)
4.11%
Variazione (1 anno)
79.12%
Paese
TW
Scambia TWi Biotechnology, Inc. (6610)

Categoria

Storico del prezzo dell'azione per TWi Biotechnology, Inc. (6610)
Prezzo di chiusura più alto: $1.18 il 2026-09-01

Prezzo di chiusura più basso: $1.95 il 2016-12-01
Storico del prezzo dell'azione di TWi Biotechnology, Inc. dal 2016 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 43.11%
2025 36.47%
2024 -13.49%
2023 13.07%
2022 -19.33%
2021 0.82%
2020 81.49%
2019 -54.47%
2018 -43.81%
2017 -42.56%
2016 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$554.69 38.33%
US
$1.05K 47.99%
NL
$150.50 522.17%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH